CA2309003A1 - Cellules ou fragments d'insecte utilises comme adjuvants d'antigenes - Google Patents

Cellules ou fragments d'insecte utilises comme adjuvants d'antigenes Download PDF

Info

Publication number
CA2309003A1
CA2309003A1 CA002309003A CA2309003A CA2309003A1 CA 2309003 A1 CA2309003 A1 CA 2309003A1 CA 002309003 A CA002309003 A CA 002309003A CA 2309003 A CA2309003 A CA 2309003A CA 2309003 A1 CA2309003 A1 CA 2309003A1
Authority
CA
Canada
Prior art keywords
adjuvant
insect
cells
antigen
epitope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002309003A
Other languages
English (en)
Other versions
CA2309003C (fr
Inventor
Gale Eugene Smith
James Debartolomeis
Andrei Igorevitch Voznesenski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Animal Health USA Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25510359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2309003(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2309003A1 publication Critical patent/CA2309003A1/fr
Application granted granted Critical
Publication of CA2309003C publication Critical patent/CA2309003C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2309003A 1997-11-07 1998-11-04 Cellules ou fragments d'insecte utilises comme adjuvants d'antigenes Expired - Lifetime CA2309003C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/965,698 US6224882B1 (en) 1997-11-07 1997-11-07 Insect cells or fractions as adjuvant for antigens
US08/965,698 1997-11-07
PCT/US1998/023472 WO1999024049A1 (fr) 1997-11-07 1998-11-04 Cellules ou fragments d'insecte utilises comme adjuvants d'antigenes

Publications (2)

Publication Number Publication Date
CA2309003A1 true CA2309003A1 (fr) 1999-05-20
CA2309003C CA2309003C (fr) 2012-10-02

Family

ID=25510359

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2309003A Expired - Lifetime CA2309003C (fr) 1997-11-07 1998-11-04 Cellules ou fragments d'insecte utilises comme adjuvants d'antigenes

Country Status (11)

Country Link
US (1) US6224882B1 (fr)
EP (2) EP1033995B1 (fr)
AT (1) ATE304369T1 (fr)
AU (1) AU1379599A (fr)
CA (1) CA2309003C (fr)
DE (1) DE69831594T2 (fr)
DK (1) DK1033995T3 (fr)
ES (1) ES2248921T3 (fr)
NZ (1) NZ504424A (fr)
PT (1) PT1033995E (fr)
WO (1) WO1999024049A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637566A (en) * 1988-08-24 1997-06-10 Southern Cross Biotech Pty. Ltd. Method of improving carcass quality by administering growth hormone
US6342216B1 (en) * 1999-03-17 2002-01-29 The Board Of Regents, The University Of Texas System Therapy of cancer by insect cells containing recombinant baculovirus encoding genes
AUPQ233799A0 (en) 1999-08-19 1999-09-09 Minister For Agriculture, Minister For Land And Water Conservation For And On Behalf Of The State Of New South Wales Recombinant sub-unit vaccine
JP2003535065A (ja) * 2000-05-31 2003-11-25 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 特異的免疫の誘導のためのアジュバント調製
US20060228326A1 (en) * 2002-10-22 2006-10-12 Fidler Isaiah J Active specific immunotherapy of cancer metastasis
EP1606419A1 (fr) 2003-03-18 2005-12-21 Quantum Genetics Ireland Limited Systemes et procedes pour accroitre la production de proteines et de lait chez des bovins laitiers
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
US8541003B2 (en) 2003-06-20 2013-09-24 Protein Sciences Corporation Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US8080255B2 (en) * 2003-07-11 2011-12-20 Novavax Inc. Functional influenza virus like particles (VLPs)
US8992939B2 (en) 2003-07-11 2015-03-31 Novavax, Inc. Highly efficient influenza matrix (M1) proteins
US8506967B2 (en) 2003-07-11 2013-08-13 Novavax, Inc. Functional influenza virus like particles (VLPs)
WO2005049794A2 (fr) 2003-11-13 2005-06-02 University Of Georgia Research Foundation, Inc. Procedes de caracterisation du virus de la bursite infectieuse
WO2005112544A2 (fr) 2004-02-19 2005-12-01 The Governors Of The University Of Alberta Polymorphismes du promoteur de la leptine et utilisations correspondantes
RS51324B (sr) 2005-04-25 2010-12-31 Merial Ltd. Vakcine protiv nipah virusa
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
CA2621666A1 (fr) * 2005-09-09 2007-03-15 Universitaet Zuerich Antigenes permettant de detection et de vacciner contre mycoplasma suis
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
EP3147296A1 (fr) 2005-11-14 2017-03-29 Merial, Inc. Thérapie génique pour traiter l'insuffisance rénale
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
WO2008009115A1 (fr) * 2006-07-18 2008-01-24 Ottawa Health Research Institute Cellules porteuses suicidaires disparates pour le ciblage tumoral de virus oncolytiques ubiquistes
EP3542815A1 (fr) 2008-11-28 2019-09-25 Boehringer Ingelheim Animal Health USA Inc. Vaccin contre la grippe aviaire recombiné et ses utilisations
EP2414386B1 (fr) 2009-04-03 2016-01-27 Merial Limited Vaccins aviaires transportés par le virus de la maladie de newcastle
EP2611460B1 (fr) 2010-08-31 2016-10-05 Merial, Inc. Vaccins contre le virus herpétique à base de vecteurs du virus de la maladie de newcastle
WO2012090073A2 (fr) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Procédés et compositions pour prédire la sensibilité à la chimiothérapie
US20140296248A1 (en) 2011-04-04 2014-10-02 Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
EP2694678A2 (fr) 2011-04-04 2014-02-12 Netherland Cancer Institute Procédés et compositions pour prédire une résistance à un traitement anti-cancéreux
US9216213B2 (en) 2011-04-20 2015-12-22 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
WO2012149038A1 (fr) 2011-04-25 2012-11-01 Advanced Bioscience Laboratories, Inc. Protéines tronquées d'enveloppe (env) du vih, procédés et compositions associés à celles-ci
CA2837375C (fr) 2011-06-01 2019-07-16 Merial Limited Administration sans aiguille de vaccins contre le vsrrp
MX350096B (es) 2011-08-12 2017-08-25 Merial Inc Preservación asistida con vacío de productos biológicos, en particular de vacunas.
WO2013093629A2 (fr) 2011-12-20 2013-06-27 Netherlands Cancer Institute Vaccins modulaires, procédés et compositions qui y sont liés
WO2013138776A1 (fr) 2012-03-16 2013-09-19 Merial Limited Nouveaux procédés pour fournir une immunité de protection à long terme contre la rage chez des animaux, basés sur l'administration d'un flavivirus défectueux en termes de réplication, exprimant la rage g
HK1216006A1 (zh) 2013-03-12 2016-10-07 Boehringer Ingelheim Animal Health USA Inc. 反向遺傳學施馬倫貝格病毒疫苗組合物，和其使用方法
ES2882374T3 (es) 2013-05-08 2021-12-01 Pharmgate Biologics Inc Vacuna para PCV2 y micoplasma
WO2016073410A1 (fr) 2014-11-03 2016-05-12 Merial, Inc. Procédés d'utilisation de formulations de vaccin par micro-aiguilles pour éliciter une immunité de protection contre le virus de la rage chez les animaux
ES3050936T3 (en) 2015-06-23 2025-12-23 Boehringer Ingelheim Vetmedica Gmbh Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof
WO2017031120A1 (fr) 2015-08-20 2017-02-23 Merial, Inc. Vaccins recombinants contre le fcv et utilisations de ceux-ci

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US5019384A (en) 1986-06-30 1991-05-28 Massachusetts Institute Of Technology Immunonodulating compositions and their use
IE872748L (en) 1986-10-16 1988-04-16 Arjomari Europ Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells
CA2003300A1 (fr) 1988-11-21 1990-05-21 Franklin Volvovitz Cutireaction et trousse pour le depistage du sida
DK0506868T4 (da) 1989-12-22 2004-04-26 Mikrogen Molekularbiol Entw Immunologisk aktive proteiner fra Borrelia burgdorferi, tilhørende testkits og vaccine
US5514375A (en) 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5503834A (en) 1990-11-20 1996-04-02 Virogenetics Corporation Measles virus recombinant poxvirus vaccine
FI933580A7 (fi) 1991-02-15 1993-10-13 Uab Research Foundation Pneumokokkiproteiinin rakennegeeni
AU672581B2 (en) 1991-03-07 1996-10-10 Virogenetics Corporation Immunodeficiency virus recombinant poxvirus vaccine
US5766597A (en) 1991-03-07 1998-06-16 Virogenetics Corporation Malaria recombinant poxviruses
DE69233158T2 (de) 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
WO1993003145A1 (fr) 1991-07-26 1993-02-18 Virogenetics Corporation Vaccin de poxvirus recombinant obtenu a partir du virus de la bursite infectieuse
US6113914A (en) 1991-08-15 2000-09-05 Smithkline Beecham Biologicals (S.A.) Osp A proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
PT100980B (pt) 1991-10-18 1999-07-30 Connaught Lab Proteinas recombinantes de borrelia, seu processo de producao, vacina contra infeccao por borrelia e agente de imunodiagnostico para a sua deteccao
ES2194010T3 (es) 1991-10-22 2003-11-16 Symbicom Ab Mejoras en el diagnostico y profilaxis de la borrelia burgdorferi.
JPH06166635A (ja) * 1992-06-18 1994-06-14 San Five Kk 免疫アジュバント
US5529780A (en) 1994-03-30 1996-06-25 Virogenetics Corporation Nucleotide and amino acid sequences of canine herpesvirus gB and gC
US5528771A (en) 1994-07-29 1996-06-25 Yudin; Beniamin Back support
EP0773993A4 (fr) 1994-08-19 2000-07-05 Gen Hospital Corp Cellules porcines traitees par genie genetique
KR20070011489A (ko) 2004-04-13 2007-01-24 도날드슨 캄파니 인코포레이티드 액체 여과용 필터 카트리지
CA2943383A1 (fr) 2014-03-21 2015-09-24 Avery Dennison Corporation Etiquettes sans face et systemes et procedes correspondants

Also Published As

Publication number Publication date
DE69831594D1 (de) 2006-01-26
NZ504424A (en) 2001-09-28
EP1033995B1 (fr) 2005-09-14
ATE304369T1 (de) 2005-09-15
EP1033995A1 (fr) 2000-09-13
AU1379599A (en) 1999-05-31
DK1033995T3 (da) 2006-01-30
US6224882B1 (en) 2001-05-01
PT1033995E (pt) 2005-11-30
WO1999024049A1 (fr) 1999-05-20
ES2248921T3 (es) 2006-03-16
CA2309003C (fr) 2012-10-02
DE69831594T2 (de) 2006-07-06
EP1611897A2 (fr) 2006-01-04
WO1999024049A9 (fr) 1999-08-12
EP1611897A3 (fr) 2007-08-15
EP1033995A4 (fr) 2001-01-10

Similar Documents

Publication Publication Date Title
CA2309003A1 (fr) Cellules ou fragments d'insecte utilises comme adjuvants d'antigenes
Roy et al. Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection
Fries et al. Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system
Höglund et al. ISCOMs and immunostimulation with viral antigens
AU696656B2 (en) Chimeric infectious bursal disease virus cDNA clones, expression products and vaccines based thereon
Plana-Duran et al. Oral immunization of rabbits with VP60 particles confers protection against rabbit hemorrhagic disease
JP7731670B2 (ja) ネコ白血病ウイルスワクチン
Marín et al. Immunogenic properties of rabbit haemorrhagic disease virus structural protein VP60 expressed by a recombinant baculovirus: an efficient vaccine
CN103555766B (zh) 兔出血症病毒样颗粒、其制备方法及应用
AU2025279721A1 (en) Multivalent feline vaccine
US20240398934A1 (en) Feline leukemia virus vaccine
EP0027347A1 (fr) Virus de la péritonite infectieuse des félins, sa préparation et vaccins le contenant
JP6280635B2 (ja) 安定化ｆｍｄｖキャプシド
AU2008347235A1 (en) PCV2 ORF2 virus like particle with foreign amino acid insertion
JP2852395B2 (ja) ネコ白血病ウイルスワクチン
Åkerblom et al. Formation and characterization of FeLV ISCOMs
Cook et al. Protection against lethal equine herpes virus type 1 (subtype 1) infection in hamsters by immune stimulating complexes (ISCOMs) containing the major viral glycoproteins
AU717628B2 (en) Feline vaccines containing chlamydia psittaci and method for making the same
AU5573196A (en) A pluripotent vaccine against enveloped viruses
RU2011132502A (ru) Иммуногенные композиции pcv2 и способы получения таких композиций
CN105296507A (zh) 拉沙热病毒样颗粒、其制备方法与应用
WO2024073766A2 (fr) Vaccin sous-unitaire sûr, compatible avec diva contre virus de la peste porcine africaine
RU2784533C2 (ru) Вакцина против вируса лейкоза кошачьих
et Vaccins lmmunogenic forms of inactivated cytokines; used with recombinant HIB virus-1 env peptide and genuine-depleted virus in vaccine against AIDS
EP0518757A1 (fr) Peptides ou polypeptides du virus BVD et virus apparentés

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20181105